



Ontogeny of plasma cytokine and chemokine concentrations across the first week of human life

Kinga K. Smolen^{a,b,*}, Alec L. Plotkin^a, Casey P. Shannon^c, Olubukola T. Idoko^{d,e}, Jensen Pak^a, Alansana Darboe^{d,e}, Simon van Haren^{a,b}, Nelly Amenyogbe^f, Scott J. Tebbutt^{c,g,h}, Tobias R. Kollmann^f, Beate Kampmann^{d,e}, Al Ozonoff^{a,b}, Ofer Levy^{a,b,i}, Oludare A. Odumade^{a,b,j,*}, on behalf of the EPIC Consortium

^a Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA

^b Harvard Medical School, Boston, MA, USA

^c PROOF Centre of Excellence, 10th Floor, 1190 Hornby Street, Vancouver, BC V6Z 2K5, Canada

^d Vaccines & Immunity Theme, Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, Gambia

^e The Vaccine Centre, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London UK

^f Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia

^g UBC Centre for Heart and Lung Innovation, Vancouver, V6T1Z4 BC, Canada

^h Department of Medicine, Division of Respiratory Medicine, UBC, Vancouver, V6T1Z4 BC, Canada

ⁱ Broad Institute of MIT & Harvard, Cambridge, USA

^j Division of Medicine Critical Care, Boston Children's Hospital, Boston, MA, USA

ARTICLE INFO

Keywords:

Cytokines
Chemokines
Ontogeny
Infant immune
Innate immune

ABSTRACT

Introduction/background & aims: Early life is marked by distinct and rapidly evolving immunity and increased susceptibility to infection. The vulnerability of the newborn reflects development of a complex immune system in the face of rapidly changing demands during the transition to extra-uterine life. Cytokines and chemokines contribute to this dynamic immune signaling network and can be altered by many factors, such as infection. Newborns undergo dynamic changes important to health and disease, yet there is limited information regarding human neonatal plasma cytokine and chemokine concentrations over the first week of life. The few available studies are limited by small sample size, cross-sectional study design, or focus on perturbed host states like severe infection or prematurity. To characterize immune ontogeny among healthy full-term newborns, we assessed plasma cytokine and chemokine concentrations across the first week of life in a robust longitudinal cohort of healthy, full-term African newborns.

Methods: We analyzed a subgroup of a cohort of healthy newborns at the Medical Research Council Unit in The Gambia (West Africa; N = 608). Peripheral blood plasma was collected from all study participants at birth (day of life (DOL) 0) and at one follow-up time point at DOL 1, 3, or 7. Plasma cytokine and chemokine concentrations were measured by bead-based cytokine multiplex assay. Unsupervised clustering was used to identify patterns in plasma cytokine and chemokine ontogeny during early life.

Results: We observed an increase across the first week of life in plasma Th1 cytokines such as IFN γ and CXCL10 and a decrease in Th2 and anti-inflammatory cytokines such as IL-6 and IL-10, and chemokines such as CXCL8. In contrast, other cytokines and chemokines (e.g. IL-4 and CCL5, respectively) remained unchanged during the first week of life. This robust ontogenetic pattern did not appear to be affected by gestational age or sex.

Conclusions: Ontogeny is a strong driver of newborn plasma-based levels of cytokines and chemokines throughout the first week of life with a rising IFN γ axis suggesting post-natal upregulation of host defense pathways. Our

Abbreviations: DOL, day of life; EPIC, Expanded Program on Immunization Consortium; HIPC, Human Immune Project Consortium; Ig, immunoglobulin; IL, interleukin; TGF- β , transforming growth factor beta; TNF, tumor necrosis factor; CXCL, C-X-C motif ligand; CCL, CC chemokine ligands; VEGF, vascular endothelial growth factor; IFN, interferon; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; FGF, fibroblast growth factor; Treg, Regulatory T cell.

* Corresponding authors at: Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, 300 Longwood Ave, Boston, MA, 02115 USA.

E-mail addresses: kinga.smolen@childrens.harvard.edu (K.K. Smolen), oludare.odumade@childrens.harvard.edu (O.A. Odumade).

<https://doi.org/10.1016/j.cyto.2021.155704>

Received 6 May 2021; Received in revised form 6 September 2021; Accepted 7 September 2021

Available online 28 September 2021

1043-4666/© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

study will prove useful to the design and interpretation of future studies aimed at understanding the neonatal immune system during health and disease.

1. Introduction

The first weeks of life represent a period of great ontogenetic change in immunity as well as marked susceptibility to infection [1,2]. Newborn vulnerability during the first few weeks of life reflects the development of a highly complex immune system [3]. As the neonatal immune system adjusts to its new *ex utero* environment, it faces many challenges, requiring better understanding and identification of markers associated immune maturation in relation to health and disease.

Cytokines and chemokines are low-molecular-weight proteins and key immune signaling molecules with pleiotropic effects on innate and adaptive immune responses [3–5]. Acting via cognate receptors on leukocytes and other host cells, the network of cytokines and chemokines is referred to as the ‘cytokine milieu’, because its function and effect depend on the target cells in diverse tissues. Cytokines and chemokines regulate complex processes such as inflammation, cellular proliferation, differentiation, and development by targeting specific cells[3].

Human plasma contains basal concentrations of a range of cytokines and chemokines [6,7]. In adults and older children, plasma cytokine and chemokine concentrations are altered by a range of factors such as age [9–14], sex, seasonality, and exercise [15–17], yet our understanding of early life ontogeny of neonatal plasma cytokine and chemokine concentrations is limited. These concentrations can be affected by maturation [16,18 19–23], as well as infectious and/or inflammatory states [24–30].

Interest in defining cytokines and chemokines in early life is driven in part by the distinct vulnerability of the newborn. 44% of under 5-year mortality occurs within the neonatal period, with ~75% of all newborn deaths occurring in the first week of life [31]. Furthermore, the majority of these deaths occur in low- and middle-income countries. Cytokines are key players in the pathology of disease and development of therapeutics[32], therefore, characterizing immune trajectories of healthy full-term infants may provide insight into how the infant immune development shapes the susceptibility to disease and responses to vaccine.

Prior studies of plasma cytokine and chemokine concentrations in infants and/or children have been limited by small sample size ($n < 20$) [33] as well as confounders such as antibiotic treatment [29,30,34] or premature [35–37] participants. Plasma concentrations of IL-1Ra, CXCL10, and TNF- α demonstrated a 60% decrease in children, aged 0.1–12.8 years of age, over time[16]. Given the rapid changes in human immunity, to our knowledge, no other study has characterized the longitudinal trajectory of plasma cytokines and chemokines over the first week of human life in a large cohort of healthy, full-term infants.

The objective of this study was to characterize the normal ontogeny of plasma cytokines and chemokine concentrations in a healthy, term African infant cohort over the first week of life. Such an effort provides insight into normal development and may inform future studies of variance from usual plasma cytokine/chemokine trajectories in the context of early life disease. Using a standardized, multiplex-based assay, we measured a diverse range of cytokine and chemokine profiles and utilized time series clustering to define ontogenetic trajectories during normal neonatal development. We found that plasma cytokine and chemokine concentrations clustered into distinct kinetic groups, including a rise in IFN γ -related cytokines across the first week, suggesting a coordinated ontogeny across the first week of human life.

2. Methods

2.1. Study design and sample collection

The clinical protocol for this study EPIC002 has been previously described[38,39]. The study is registered on clinicaltrials.gov as NCT03246230. In brief, mothers-infant pairs were consented and enrolled at time of delivery at the Medical Research Council (MRC) Unit at the London School of Hygiene and Tropical Medicine in The Gambia. HIV- and Hepatitis B-negative mothers 18 years or older, were enrolled. Infants were enrolled if >36 weeks of gestational age (as determined by Ballard scoring), with Apgar scores >8 at 5 min and birth weight >2.5 kg. Peripheral blood samples (max volume 2 ml) were collected from infants using sterile sodium heparin tubes (Becton Dickinson). Four time points were collected: Visit 1 (V1), was collected within the first 24 h of life (Day of Life (DOL)0); while the Visit 2 (V2) sample was collected at either DOL1, or DOL3, or DOL7. Plasma samples were processed for analysis as previously published [40]. All plasma samples were stored at –80 °C until use. Local and International IRB committees approved all protocols utilized.

2.2. Cytokine and chemokine qualification methods

Reagents: Milliplex Human Cytokine/Chemokine MAGNETIC BEAD Premixed 41 Plex Kit. (Millipore cat. #HCYTMAg-60K-PX41), Dulbecco’s phosphate-buffered saline (dPBS, cat. #14190), and Corning Cell-BIND® 384 well plates (cat. #CLS3764).

Cytokine/Chemokine assay: The Luminex assay was performed across 7 Luminex plates. Plasma was diluted 1:2 in dPBS. Cytokines and chemokines were measured using the 41-plex Milliplex Map Kit (cat. #HCYTMAg-60K-PX41), which contains; *sCD40L*, *EGF*, *FGF-2*, *Flt-3 ligand*, *Fractalkine*, *G-CSF*, *GM-CSF*, *GRO (CXCL1)*, *IFN- α 2*, *IFN- γ* , *IL-1 α* , *IL-1 β* , *IL-1ra*, *IL-2*, *IL-3*, *IL-4*, *IL-5*, *IL-6*, *IL-7*, *IL-8 (CXCL8)*, *IL-9*, *IL-10*, *IL-12 (p40)*, *IL-12 (p70)*, *IL-13*, *IL-15*, *IL-17A*, *IP-10 (CXCL10)*, *MCP-1 (CCL2)*, *MCP-3 (CCL7)*, *MDC (CCL22)*, *MIP-1 α (CCL3)*, *MIP-1 β (CCL4)*, *PDGF-AB/BB*, *RANTES (CCL5)*, *TGF- α* , *TNF- α* , *TNF- β* , *VEGF*, *Eotaxin (CCL11)*, and *PDGF-AA*. Plasma samples were assayed using a 384-well plate platform following the manufacturer’s instructions, including the provided controls. Samples were analyzed using a Flexmap 3D system with Luminex xPONENT software (Luminex Corp.; Austin, TX, USA).

The xPONENT software files were processed using the *drLumi R* package. We fitted 4-parameter logistic, 5-parameter logistic, and exponential functions to the dilution series data for each analyte using the *scluminex* function implemented in *drLumi* (*drLumi::scluminex()*), selecting the best fit function in each case. These were then used to determine the lower and upper limits of detection and quantification for each analyte and plate. Analytes that fell below or above these values were imputed to the lower or upper limit of quantification, respectively. For a given sample and analyte, if readings were <30 beads, concentration values were discarded. Samples with all analytes below the lower limit of detection (LLD) were also excluded from analysis.

2.3. Statistical analysis

Cytokine and chemokine values were log transformed. ComBat (R package) was used to carry out batch-correction (normalization) across plates based on plate-specific bias identified by PCA. A universal reference standard sample set was added to each plate and used as a bridge sample set across plates.

Cytokines or chemokines with near-zero variance were identified

using the nearZeroVar function from the caret R package (low percentage of unique values; high ratio of the frequency of the first and second most frequent values). Near-zero variance cytokines (IL-2, IL-3, and IL-17A) had few values above their respective LLD and were excluded.

Principal component analysis (PCA) was employed to summarize variability in the \log_{10} -transformed cytokine concentration and fold change datasets, using R packages FactoMineR_2.3 and factoextra_1.0.7. All cytokines were centered and scaled to unit variance.

Statistical differences in cytokine levels between DOL were assessed using the Wilcoxon signed-rank test. Fold-change values were calculated by indexing untransformed concentration values to DOL0, then \log_{10} -transforming. P-values < 0.05 were considered significant, and the Holm-Bonferroni method using $n = 38$ cytokines was used to adjust for multiple comparisons. Associations of cytokines with biological sex, ethnicity, maternal age, and gestational age were tested to assess if there were any other factors with significant effects on cytokine concentrations. Each cytokine was modeled as a dependent variable in separate linear models, with the variable of interest, a Visit term, and an interaction term as independent variables.

To identify groups of cytokine and chemokines with common trajectories across the first week of life, we performed time series clustering. The \log_{10} -transformed cytokine concentrations were first standardized. Average time series were constructed by taking the mean of each cytokine at each DOL. The distances between cytokine time series were calculated with dynamic time warping, using the R package dtw_1.21-3 [41]. This approach yielded improved time series clusters compared to the Euclidean distance metric. We then performed complete-linkage agglomerative hierarchical clustering on the resulting cytokine distances. Five clusters were identified by maximizing the average silhouette width between clusters.

To assess the robustness of our clustering approach, we repeated the procedure across 1000 bootstrap re-samplings using 90% of the data (random selection of 540 out of the 608 participants), and used the frequencies with which cytokines co-clustered to calculate the final groupings, as previously described [42]. In addition, we compared our clusters to those obtained when carrying out consensus clustering on the two time points from each individual, without averaging, to preserve individual-level information [43]. Both methodologies were found to produce similar cytokine and chemokine clusters.

3. Results

3.1. Cohort enrollment and baseline characteristics of study participants

608 healthy Gambia mother-newborn pairs from the EPIC-002A cohort were analyzed in this study. The cohort demographic table (Table 1) indicates that the plurality of mothers (29.1%) were 25–29 years old, followed by age 20–24 years old (22.2%) and then age 30–34 (20.7%). An approximately equal ratio of male (50.7%) to female (49.3%) newborns were enrolled. The average birth weight was 3.16 kg. A few ($n = 4$, 0.7%) preterm newborns (<37 weeks gestation) were enrolled within the cohort, but the majority (86.2%) of newborns were early term (≥ 37 to <38 weeks gestation) or full term (≥ 38 to <40 weeks gestation). Breastfeeding was initiated for 88.5% of infants at delivery and continued after the first day of life (>98.8%) until four months of age for infants in this cohort.

3.2. Association of cytokine and chemokine concentration and demographic factors

Initially, we investigated the associations between plasma cytokine and chemokine concentrations and physical findings at birth, as these can be early indicators of post-natal conditions (i.e., early onset sepsis). There were no significant differences observed in plasma concentrations of cytokines and chemokines in relation to respiratory rate, heart rate,

Table 1
Demographic characteristics of the study participants.

Characteristics	Frequency (n)	Percent (%)
Sex of Baby:		
Female/Male	300/308	49.3/50.7
Birth weight (kg):		
Avg (\pm SEM)	3.16 \pm 0.015	
Age of mothers (years):		
18–19 years	26	4.3
20–24 years	135	22.2
25–29 years	177	29.1
30–34 years	126	20.7
35–39 years	109	17.9
40–45 years	35	5.8
Term of Baby:		
Preterm (<37 weeks)	4	0.7
Early term (37–38 weeks)	150	24.7
Full term (39–40 weeks)	374	61.5
Late term (>40 weeks)	80	13.2
Ethnicity of Baby:		
Mandinka	291	47.9
Jola	96	15.8
Fula	79	13.0
Wollof	68	11.2
Serahule	22	3.6
Others	52	8.6
Frequency of breastfeeding:		
Visit 1 (Yes/No)	538/70	88.5/11.5
Visit 2 (Yes/No)	601/7	98.8/1.2

weight, length, head circumference, or temperature at birth (data not shown).

We also examined the correlation between plasma cytokine and chemokine concentrations and demographic clinical data over the first week of life. No significant correlations were observed between demographic parameters such as sex, maternal age, gestational age or breastfeeding with cytokines and chemokines measured at DOL 1, 3, or 7.

3.3. Ontogenetic changes across the first week of life

To identify potential ontogenetic changes, we measured the concentration of the plasma cytokines and chemokines in 608 healthy Gambia mother-newborn pairs ($n = 202$ at DOL1, $n = 206$ at DOL3, $n = 200$ at DOL7) over the first week of life. Principal component analysis (PCA) demonstrated the expression of cytokines and chemokines. The first two principal components (PC1 and PC2) accounted for 35.4% of total variance (Fig. 1A). PC2 captures the differences between Visit 1 and Visit 2, accounts for ~10% of total variance. PC3 also contained some variance information from ontogenetic changes between Visit 1 and Visit 2 (Supp Fig. 1A; ~6.6% of total variance). The PCA loadings illustrate that TGF α , CXCL8, sCD40L, CCL4, IL-6, and PDGF-AB/BB are elevated at birth (Visit 1) relative to Visit 2 (DOL 1, 3, or 7). Fig. 1B lists the top 15 contributing cytokines and chemokines, while Supp Fig. 1B demonstrates all cytokines and chemokines.

3.4. Increase of plasma cytokine and chemokine ontogeny changes with the increase of age

We tested whether the relative abundances of individual cytokines and chemokines changed across the first week of life (Fig. 1C; Supplementary Table 1). At DOL1, plasma concentrations of CXCL10, IFN γ , CCL2, and IL-5 were all significantly higher over DOL0, while EGF, sCD40L, G-CSF, and IL-6 are significantly lower. DOL3 revealed more pronounced differences from DOL0, with greater increases in CXCL10, IFN γ , IL-5, and IL-1 α , and a downregulation of CXCL8, TGF α , IL-6, IL-10, PDGF-AB/AA, and G-CSF. Lastly, at DOL7, IFN γ , CXCL10, and IL-5




Fig. 1. Ontogeny of plasma cytokines and chemokines over the first week of life. A. Principal component analysis (PCA) demonstrating ontogeny of plasma cytokine and chemokines. PCA was used to plot \log_{10} -transformed plasma cytokine/chemokine concentrations and revealed sample clustering by Visit (age) in EPIC-HIPC Gambia cohort. B. Cytokine loadings on principal components 1 and 2. C. Volcano plots provide further resolution of the ontogeny of cytokine and chemokines. Volcano plots with cytokine/chemokines significantly increased over day of life (DOL) 0 in EPIC-HIPC Gambia cohort across the first week of life. Significant cytokines or chemokines (p -value < 0.01, absolute \log_2 [fold change vs DOL0] > 0.2) are marked in red with abbreviated cytokine/chemokine names. A paired Wilcoxon was used to test for cytokine significance. (n = 608 participants for Visit 1 and Visit 2: 202 DOL1, 206 DOL3, 200 DOL7).

continue to be significantly upregulated, while CXCL8, TGFA, IL-6, CCL4, IL-10, IL-1RA, and G-CSF, were significantly downregulated.

3.5. Plasma cytokine and chemokine cluster by time series analysis during the first week of life

Time series clustering highlighted specific patterns of plasma cytokine and chemokine concentrations over the first week of life (Fig. 2). Hierarchical clustering of mean standardized, dynamic time warped cytokine and chemokine profiles across the first week of life revealed five clusters of cytokines (Fig. 2B, Supp Fig. 2). The trajectories of these clusters are shown in Fig. 2B, along with the mean trajectories of their component cytokines and chemokines. Error bars represent 95% confidence intervals for the cluster mean (Supp Table 1). Paired t-tests were performed to test whether the cluster concentrations were significantly different between DOL0 and subsequent days of life (Supp Fig. 2).

As a sensitivity analysis, we compared our cluster method to an independent validation method [43]. We compared the consensus values of both methods, which can be interpreted as the frequency that cytokines are placed into the same cluster across repeated runs [43]. The average consensus for clusters 1–5 was 79.4% using the main methodology and 53.9% using the validation methodology.

Representative cytokines and chemokines for each cluster are shown in Fig. 2C to illustrate the variation within groups. Paired t-tests of cytokine concentrations between DOL0 and the follow-up visits were employed to assess for significance. The detailed pattern of each cytokine and chemokine was analysed as standardized \log_{10} - as well as raw concentrations and depicted in Supplementary Fig. 2A and 2B, respectively. This analysis suggested that there are distinct trajectories for

different groups of cytokines and chemokines during the first week of life.

4. Discussion

In this study, plasma cytokines and chemokines were measured in a longitudinal cohort of healthy, full-term Gambian newborns throughout the first week of life, using highly standardized, quantitative multiplex protein assays. A variety of longitudinal changes were observed. Plasma concentrations of CXCL10, GM-CSF, IFNY, and IL-5 increased over the first week of life while those of CCL4, CXCL8, G-CSF, IL-10, IL-1RA, IL-6, and TGFA decreased. We thus observed that ontogeny is a strong driver of human neonatal plasma cytokine and chemokine concentrations.

Cytokines and chemokines are key signaling proteins that act via cognate receptors to shape immune responses [6]. In early life, cytokines and chemokines play a crucial role in the maturation and development of lymphoid progenitors [44]. Our findings indicate a significant increase of Th1 cytokines and a significant decrease of pro-inflammatory and regulatory cytokines and chemokines across the first week of life. We observed a significant increase of Th1-polarizing cytokines, including IFNY, IFNY-inducible CXCL10 (IP10), GM-CSF, which may contribute to progressive development of cell mediated immunity with age, as well as IL-5, a Th2-polarizing cytokine that contributes to eosinophil activation. Plasma IFNY concentrations rose significantly though modestly across the first week of life, along with those of IL-12 and TNFA, consistent with the generally tight regulation of cytokines and limited ability of human neonatal leukocytes to produce these cytokines [33,45,46]. Of note, IFNY is important to early life host defense [47] as: 1) low birthweight newborns who are highly susceptible to




Fig. 2. Time series analysis across the first week of life demonstrates distinct cytokine/chemokine cluster patterns. **A.** Time series clustering. Hierarchical clustering was performed to group cytokines and chemokines based on their mean time series. **B.** Cytokine traces by cluster. The mean cluster (solid line) and cytokine (dashed line) traces for each day of life (DOL) show consistent trajectories within each cluster across the first week of life. Error bars represent 95% confidence intervals for the cluster mean. The cytokines in clusters 1 and 2 exhibit small changes over the first week of life, with some reaching transient troughs or peaks at DOLs 1 and 3. The cytokines in cluster 3 rise slowly across the first week of life. Cluster 4, which primarily contains inflammation-associated cytokines such as IL-6 and IL-10, shows a steady decrease across the first week of life. The cytokines in cluster 5, including IFN γ and CXCL10, increase rapidly between birth and DOL1, then peak and reverse course by DOL3. **C.** Representative cytokines were chosen for each cluster to show the variation within groups. Statistical comparison employed T-tests on standardized cytokine concentrations for paired samples between DOL0 and the follow-up visit. (****: $p < 0.0001$, ***: $p < 0.001$, **: $p < 0.01$, *: $p < 0.05$. $n = 608$: 202 DOL1, 206 DOL3, 200 DOL7.)

infection are relatively deficient in IFN γ production[48]; 2) Addition of IFN- γ to human newborn blood *in vitro* enhanced innate immune function including leukocyte responses to bacteria and plasma opsonophagocytic activity; and 3) IFN γ R deficient children present in early life with severe mycobacterial infections[49]. Thus the rise of IFN and IFN-associated CXCL10 can be viewed as a gradual ontogenetic enhancement in the ability to confront intracellular pathogens.

Newborns emerge out of a highly regulated maternofetal environment aimed at protecting non-self (the fetus) from self, the maternal immune system, while *in utero*. For example, the placenta produces mediators such as progesterone and prostaglandin to promote a Th2 bias in the fetus [50,51]. Human neonatal antigen-presenting cells demonstrate reduced stimulus-induced production of Th1- and Th17 -type cytokines coupled with preserved production of Th2 -type cytokines, contributing to an anti-inflammatory environment *in utero* that reduces the risk of abortion or pre-term delivery[46].

Although the *in utero* environment is highly tolerogenic, due to a variety of immunosuppressive mechanisms [52–54], birth itself is a controlled inflammatory process. Collaboration between innate and adaptive immune responses is required to sustain pregnancy [55], and disturbance of this balance occurs during physiological labor. In contrast to the Th1-type cytokine increase, we found a significant decrease of CCL4, CXCL8, IL-6, IL-1RA, G-CSF, IL-10, and TGF α over the first week of life. A decline in pro-inflammatory and pro-resolution cytokines and chemokines including CXCL8, CCL4, and IL-6 [56], along with anti-inflammatory factors including IL-10 and TGF α , might reflect resolution of the birthing process.

After birth, the immune system begins to transition towards a

complex and microbe-rich extra-uterine environment. The establishment of the gut microbiome begins at birth[57] and continues to develop until ~ 3 years of age [58–60], and maintains interplay with the developing immune system[61]. The increase in plasma concentrations of IFN $\alpha 2$, IL-12p70, IL-13, IL-1a, IL-9, and TNF α support an ontogeny-based transition away from the highly regulated maternofetal environment towards the more diverse *ex utero* environment. A previous study looking at 24 matched samples, found no difference between maternal blood and newborn cord blood from elective Cesarean deliveries with respect to plasma concentrations of IL-6, CXCL-8, IL-10, and IL1-RA (PMID 26136749). Our study, focused on vaginal deliveries, was not designed to correlate maternal cytokine levels with that of the neonates, though based on the aforementioned study we hypothesize that cytokine concentrations at birth likely correlate with those in maternal plasma. Of note, plasma concentrations of certain cytokines such as IL-6 are higher in vaginal vs. C-section delivery[29].

We did not observe any significant differences in cytokine concentrations between infants who were breastfed vs those who were formula feed (data not shown). Despite this observation, it remains possible that breast milk cytokine concentrations may impact those of infant plasma[62,63], as: 1) analysis of plasma cytokines and chemokine concentrations beyond the first week of life may demonstrate differences between breastfed and non-breastfed levels; 2) detecting potential differences in plasma cytokines due to breastfeeding may require specific focus on mucosal immunity/oral tolerance, as has been reviewed[64], and correlations with maternal plasma cytokine/chemokine concentrations as well as maternal breastmilk cytokine/chemokine concentrations that differ by parity status[62]. Overall, there is need for additional

studies on the relation of method of delivery [29], breast- vs formula-feeding, and early life immune ontogeny.

Consistent with other studies of cytokines and chemokines in early life [34,65], we did not observe sex-related differences in plasma cytokine and chemokine concentrations. Previous studies in healthy children >1 month old have found age- and sex- differences in plasma cytokines and chemokines, potentially due to sex hormones [16,18,23,66]. Given that there are age-dependent sex differences later in life [67,68], future studies should investigate at which timepoint these sex-dependent cytokine changes occur and whether any such changes correspond to sex-specific differences in innate and adaptive immunity.

Given growing evidence of rapid changes in infant immunity [40], our study was designed to capture clinical and cytokine/chemokine data from the day of birth. Cytokines and chemokines in Cluster 1 (CCL3, CX3CL1, CXCL1, EGF, IL-12p40, PDGF-AB/BB, sCD40L, VEGF) and Cluster 2 (CCL2, CCL5, CCL7, Eotaxin, IL-15, IL-4, IL-7, PDGF-AA, TNF β) play a crucial role in activating or mediating the host immune response to pathogens. These changes over the first week of life illustrate the dynamic nature of the early life immune system. Several reviews detail the function of each of these cytokines and chemokines [16,18,19–23].

Our results have potential translational applications. Compared to adults, infants have increased susceptibility to infection, yet most preventative strategies for neonates rely upon our understanding of the adult immune system. Inflammatory protein markers such as those regulated by IL-6, like C-reactive protein (CRP), are important clinical analytes for early onset neonatal sepsis [69,70]. In infants, G-CSF, IL-6, CXCL8 (IL-8), and TNF- α have been identified as potential markers of Gram-negative bacteremia in the neonatal intensive care unit [71]. There remains an unmet need to define effective biomarkers of early onset sepsis, defined as less than 72 h in pre-term infants, and less than 7 days in term infants [69,72].

The age-dependent changes observed here suggest that plasma cytokines and chemokines have day of life-specific normal ranges, with future studies needed to further validate this finding. We observed a clear plasma cytokine/chemokine ontogeny signature during the first week of life. As cytokines, such as IFN- γ and IL-1 β , can contribute to “innate memory” or trained immunity [73–75], future studies should investigate the relationship of these plasma cytokines, both at baseline and after infection or immunization, on measures of trained immunity. Indeed, characterizing immune trajectories in healthy newborns will help address questions concerning how distinct early life immunity shapes susceptibility to disease.

Our study also has a number of limitations. Although the number of infants included in this study is substantial, samples were collected at a single study site in The Gambia (West Africa), requiring further studies to assess the generalizability of these findings. Nevertheless, our observation of significant changes in the cytokine IFN γ and related chemokine, the IFN γ -inducible CXCL10, with similar trajectories noted in geographically and genetically distinct newborns in Papua New Guinea [39] suggests that the patterns we observed have broader applicability. Secondly, we do not yet know whether the observed trajectories remain consistent between the first week of life and the remainder of the vulnerable neonatal period, defined as first 28 days of life. This is a key question in the field of immune ontogeny and will require further study.

5. Conclusion

Our findings demonstrate an age-dependent pattern of plasma cytokines and chemokines in healthy, term Gambian infants, representing an ontogenetic trajectory reflective of the initiation of a post-birth transition from a Th2-polarized to a more balanced Th1/Th2 immune state. Our findings help define the baseline trajectories of plasma cytokines and chemokines in healthy newborns and will inform future studies to correlate plasma cytokines and chemokines with responses to immune challenge such as immunization, as well as deviations from

healthy trajectories due to infection or other diseases.

Funding

This work was supported by funds from the National Institute of Health (NIH), National Institute of Allergy and Infectious Disease (NIAID) division as part of the Human Immunology Project Consortium (U19AI118608) to OL, and funds from the Boston Children’s Global Health Program and an NIH Loan Repayment Program award, the National Institute on Minority Health and Health Disparities (NIMHD) to OAO. The *Precision Vaccines Program* is supported in part by the Department of Pediatrics and Chief Scientific Officer of Boston Children’s Hospital. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or Boston Children’s Hospital.

Author contributions

This manuscript was written by KKS and OAO; edited by BK, SJT, OL; OL, BK, TRK conceptualized the EPIC study; ALP, KKS, CPS performed the formal analysis; AO, CPS provided statistical analyses input; OTI, AD with the members of EPIC listed below lead or assisted with sample processing, clinical data capture, data quality control, data curation; AO lead the data deposition team; KKS lead the investigation and optimized the methodology of cytokine/chemokine assay used; OAO, JP, ALP, SvH, NA provided methodological support. The authors listed above reviewed the final copy as submitted.

Declaration of Competing Interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: OL is a named inventor on several patents related to microphysiologic platforms that model human immunity *in vitro*, anti-infective proteins, and vaccine adjuvants. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

We thank our study participants, their families, our colleagues at the Medical Research Council Unit at London School of Hygiene and Tropical Medicine in The Gambia and the field team data collectors. We also thank *Precision Vaccines Program* administrative team, including Diana Vo and Gloria Gasangwa for their support, as well as the BCH Medical Library staff for assistance with literature review. The authors acknowledge the support of the Global Health Program at Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA.

Data deposition

To ensure public availability, deidentified data described in this article, including plasma cytokine and chemokine concentrations, were archived on NIH/NIAID’s ImmPort repository (<https://immport.niaid.nih.gov/home>) under accession numbers SDY1538.

Appendix A. Supplementary material

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.cyto.2021.155704>.

References

- [1] M.K. Hostetter, What we don’t see, *N. Engl. J. Med.* 366 (14) (2012) 1328–1334, <https://doi.org/10.1056/NEJMra1111421>.

- [2] R. Bortolussi, P. Henneke, T. Kollmann, Host defense against common early life-threatening infections, *Clin. Dev. Immunol.* 2013 (2013) 1–2, <https://doi.org/10.1155/2013/350808>.
- [3] J.R. Tisoncik, M.J. Korth, C.P. Simmons, J. Farrar, T.R. Martin, M.G. Katze, Into the eye of the cytokine storm, *Microbiol. Mol. Biol. Rev.* 76 (1) (2012) 16–32, <https://doi.org/10.1128/MMBR.05015-11>.
- [4] M. Akdis, et al., Interleukins (from IL-1 to IL-38), interferons, transforming growth factor beta, and TNF-alpha: Receptors, functions, and roles in diseases, *J. Allergy Clin. Immunol.* 138 (2016) 984–1010, <https://doi.org/10.1016/j.jaci.2016.06.033>.
- [5] S.R. Holdsworth, P.-Y. Gan, Cytokines: Names and Numbers You Should Care About, *Clin. J. Am. Soc. Nephrol.* 10 (12) (2015) 2243–2254, <https://doi.org/10.2215/CJN.07590714>.
- [6] I. Agalliu, X. Xue, M. Cushman, E. Cornell, A.W. Hsing, R.C. Kaplan, K. Anastos, S. Rajpathak, G.Y.F. Ho, Detectability and reproducibility of plasma levels of chemokines and soluble receptors, *Results Immunol.* 3 (2013) 79–84, <https://doi.org/10.1016/j.rinim.2013.07.001>.
- [7] A. Biancotto, A. Wank, S. Perl, W. Cook, M.J. Olnes, P.K. Dagur, J.C. Fuchs, M. Langweiler, E. Wang, J.P. McCoy, A. Boasso, Baseline levels and temporal stability of 27 multiplexed serum cytokine concentrations in healthy subjects, *PLoS ONE* 8 (12) (2013) e76091, <https://doi.org/10.1371/journal.pone.0076091>.
- [8] A. Gasparoni, L. Ciardelli, A. Avanzini, A.M. Castellazzi, R. Carini, G. Rondini, G. Chirico, Age-related changes in intracellular TH1/TH2 cytokine production, immunoproliferative T lymphocyte response and natural killer cell activity in newborns, children and adults, *Biol. Neonate* 84 (4) (2003) 297–303, <https://doi.org/10.1159/000073638>.
- [9] I.M. Chalmers, G. Janossy, M. Contreras, C. Navarrete, Intracellular cytokine profile of cord and adult blood lymphocytes, *Blood* 92 (1998) 11–18.
- [10] S. Ilangumaran, G. Ferbeyre, Editorial: Cytokines in inflammation, aging, cancer and obesity, *Cytokine* 82 (2016) 1–3, <https://doi.org/10.1016/j.cyto.2016.03.011>.
- [11] A.A. Sas, Y. Jamshidi, D. Zheng, T. Wu, J. Korf, B.Z. Alizadeh, T.D. Spector, H. Snieder, The age-dependency of genetic and environmental influences on serum cytokine levels: a twin study, *Cytokine* 60 (1) (2012) 108–113, <https://doi.org/10.1016/j.cyto.2012.04.047>.
- [12] H. Jeon, G.I. Mun, Y.C. Boo, Analysis of serum cytokine/chemokine profiles affected by aging and exercise in mice, *Cytokine* 60 (2) (2012) 487–492, <https://doi.org/10.1016/j.cyto.2012.07.014>.
- [13] O.B. Bakker, R. Aguirre-Gamboa, S. Sanna, M. Oosting, S.P. Smeeckens, M. Jaeger, M. Zorro, U. Vösa, S. Withoff, R.T. Netea-Maier, H.J.P.M. Koenen, I. Joosten, R. J. Xavier, L. Franke, L.A.B. Joosten, V. Kumar, C. Wijmenga, M.G. Netea, Y. Li, Integration of multi-omics data and deep phenotyping enables prediction of cytokine responses, *Nat. Immunol.* 19 (7) (2018) 776–786, <https://doi.org/10.1038/s41590-018-0121-3>.
- [14] E.J. Goetzl, M.-C. Huang, J. Kon, K. Patel, J.B. Schwartz, K. Fast, L. Ferrucci, K. Madara, D.D. Taub, D.L. Longo, Gender specificity of altered human immune cytokine profiles in aging, *FASEB J.* 24 (9) (2010) 3580–3589, <https://doi.org/10.1096/fbs2.v24.910.1096/fj.10-160911>.
- [15] M.L. Decker, Y. Gotta, S. Wellmann, N. Ritz, Cytokine profiling in healthy children shows association of age with cytokine concentrations, *Sci. Rep.* 7 (2017) 17842, <https://doi.org/10.1038/s41598-017-17865-2>.
- [16] R. Ter Horst, et al., Host and Environmental Factors Influencing Individual Human Cytokine Responses, e1113, *Cell* 167 (2016) 1111–1124, <https://doi.org/10.1016/j.cell.2016.10.018>.
- [17] M.L. Decker, M.P. Grobusch, N. Ritz, Influence of Age and Other Factors on Cytokine Expression Profiles in Healthy Children—A Systematic Review, *Front. Pediatr.* 5 (2017) 255, <https://doi.org/10.3389/fped.2017.00255>.
- [18] E.D. Bernstein, D.M. Murasko, Effect of age on cytokine production in humans, *Age (Omaha)* 21 (4) (1998) 137–151, <https://doi.org/10.1007/s11357-998-0024-6>.
- [19] F. Hoffmann, et al., Intracellular T-cell cytokine levels are age-dependent in healthy children and adults, *Eur. Cytokine Netw.* 16 (2005) 283–288.
- [20] V. Wiegering, et al., Age-related changes in intracellular cytokine expression in healthy children, *Eur. Cytokine Netw.* 20 (2009) 75–80, <https://doi.org/10.1684/ecn.2009.0149>.
- [21] M. Lappalainen, M. Roponen, J. Pekkanen, K. Huttunen, M.R. Hirvonen, Maturation of cytokine-producing capacity from birth to 1 yr of age, *Pediatr. Allergy Immunol.* 20 (2009) 714–725, <https://doi.org/10.1111/j.1399-3038.2009.00865.x>.
- [22] G. Kleiner, A. Marcuzzi, V. Zanin, L. Monasta, G. Zauli, Cytokine levels in the serum of healthy subjects, *Mediators Inflamm.* 2013 (2013) 1–6, <https://doi.org/10.1155/2013/434010>.
- [23] N. Chauhan, S. Tiwari, U. Jain, Potential biomarkers for effective screening of neonatal sepsis infections: An overview, *Microb. Pathog.* 107 (2017) 234–242, <https://doi.org/10.1016/j.micpath.2017.03.042>.
- [24] Y. Fan, J.-L. Yu, Umbilical blood biomarkers for predicting early-onset neonatal sepsis, *World J. Pediatr.* 8 (2) (2012) 101–108, <https://doi.org/10.1007/s12519-012-0347-3>.
- [25] M.-A. Hincü, G.-I. Zonda, G.D. Stanciu, D. Nemescu, L. Padurarü, Relevance of Biomarkers Currently in Use or Research for Practical Diagnosis Approach of Neonatal Early-Onset Sepsis, *Children (Basel)* 7 (12) (2020) 309, <https://doi.org/10.3390/children7120309>.
- [26] J. Reis Machado, D.F. Soave, M.V. da Silva, L.B. de Menezes, R.M. Etchebehere, M. L.G.D.R. Monteiro, M. Antônia dos Reis, R.R.M. Corrêa, M.R.N. Celes, Neonatal sepsis and inflammatory mediators, *Mediators Inflamm.* 2014 (2014) 1–10, <https://doi.org/10.1155/2014/269681>.
- [27] X. Qiu, et al., Interleukin-6 for early diagnosis of neonatal sepsis with premature rupture of the membranes: A meta-analysis, *Medicine (Baltimore)* 97 (2018) e13146, <https://doi.org/10.1097/MD.00000000000013146>.
- [28] C.U. Ebenebe, et al., Interleukin-6 elevation in healthy neonates, *J. Perinatol.* 40 (2020) 294–298, <https://doi.org/10.1038/s41372-019-0550-3>.
- [29] B.C. Oosterloo, B. van't Land, W. de Jager, N.B. Rutten, M. Klöpping, J. Garssen, A. M. Vlieger, R.M. van Elburg, Neonatal Antibiotic Treatment Is Associated With an Altered Circulating Immune Marker Profile at 1 Year of Age, *Front. Immunol.* 10 (2019), <https://doi.org/10.3389/fimmu.2019.0293910.3389/fimmu.2019.02939.s001>.
- [30] M.J. Sankar, C.K. Natarajan, R.R. Das, R. Agarwal, A. Chandrasekaran, V.K. Paul, When do newborns die? A systematic review of timing of overall and cause-specific neonatal deaths in developing countries, *J. Perinatol.* 36 (S1) (2016) S1–S11, <https://doi.org/10.1038/jp.2016.27>.
- [31] D.V. Kalvakolanu, Twenty five years of Cytokine: on a forward path to exciting discoveries of pathological mechanisms and therapeutics, *Cytokine* 98 (2017) 1–3, <https://doi.org/10.1016/j.cyto.2017.08.008>.
- [32] M. Jeljeli, V. Guérin-El Khourotj, B. Pédrón, P. Gressens, O. Sibony, G. Sterkers, Ontogeny of cytokine responses to PHA from birth to adulthood, *Pediatr. Res.* 86 (1) (2019) 63–70, <https://doi.org/10.1038/s41390-019-0383-y>.
- [33] S. Lusyati, C.V. Hulzebos, J. Zandvoort, P.J. Sauer, Levels of 25 cytokines in the first seven days of life in newborn infants, *BMC Res. Notes* 6 (2013) 547, <https://doi.org/10.1186/1756-0500-6-547>.
- [34] T.F. McElrath, et al., Blood protein profiles of infants born before 28 weeks differ by pregnancy complication, 418 e411–418 e412, *Am. J. Obstet. Gynecol.* 204 (2011), <https://doi.org/10.1016/j.ajog.2010.12.010>.
- [35] S. Kamdar, et al., Perinatal inflammation influences but does not arrest rapid immune development in preterm babies, *Nat. Commun.* 11 (2020) 1284, <https://doi.org/10.1038/s41467-020-14923-8>.
- [36] D.D. Briana, et al., Fetal concentrations of the growth factors TGF-alpha and TGF-beta1 in relation to normal and restricted fetal growth at term, *Cytokine* 60 (2012) 157–161, <https://doi.org/10.1016/j.cyto.2012.06.005>.
- [37] O.T. Idoko, K.K. Smolen, O. Wariri, A. Imam, C.P. Shannon, T. Dibasse, J. Diray-Arce, A. Darboe, J. Strandmark, R. Ben-Othman, O.A. Odumade, K. McEnaney, N. Amenogbe, W.S. Pomat, S. van Haren, G. Sanchez-Schmitz, R.R. Brinkman, H. Steen, R.E.W. Hancock, S.J. Tebbutt, P.C. Richmond, A.H.J. van den Biggelaar, T.R. Kollmann, O. Levy, A.I. Ozonoff, B. Kampmann, Clinical Protocol for a Longitudinal Cohort Study Employing Systems Biology to Identify Markers of Vaccine Immunogenicity in Newborn Infants in The Gambia and Papua New Guinea, *Front. Pediatr.* 8 (2020), <https://doi.org/10.3389/fped.2020.00197>.
- [38] A.H. Lee, C.P. Shannon, N. Amenogbe, T.B. Bennike, J. Diray-Arce, O.T. Idoko, E. E. Gill, R. Ben-Othman, W.S. Pomat, S.D. van Haren, K.-A. Cao, M. Cox, A. Darboe, R. Falsafi, D. Ferrari, D.J. Harbeson, D. He, C. Bing, S.J. Hinshaw, J. Ndure, J. Njie-Jobe, M.A. Pettengill, P.C. Richmond, R. Ford, G. Saleu, G. Masiria, J.P. Matlam, W. Kirarock, E. Roberts, M. Malek, G. Sanchez-Schmitz, A. Singh, A. Angelidou, K. K. Smolen, R.R. Brinkman, A.I. Ozonoff, R.E.W. Hancock, A.H.J. van den Biggelaar, H. Steen, S.J. Tebbutt, B. Kampmann, O. Levy, T.R. Kollmann, Dynamic molecular changes during the first week of human life follow a robust developmental trajectory, *Nat. Commun.* 10 (1) (2019), <https://doi.org/10.1038/s41467-019-08794-x>.
- [39] T.B. Bennike, B. Fatou, A. Angelidou, J. Diray-Arce, R. Falsafi, R. Ford, E.E. Gill, S. D. van Haren, O.T. Idoko, A.H. Lee, R. Ben-Othman, W.S. Pomat, C.P. Shannon, K. K. Smolen, S.J. Tebbutt, A.I. Ozonoff, P.C. Richmond, A.H.J.V.D. Biggelaar, R.E. W. Hancock, B. Kampmann, T.R. Kollmann, O. Levy, H. Steen, Preparing for Life: Plasma Proteome Changes and Immune System Development During the First Week of Human Life, *Front. Immunol.* 11 (2020), <https://doi.org/10.3389/fimmu.2020.578505>.
- [40] T. Giorgino, Computing and Visualizing Dynamic Time Warping Alignments in R: The dtw Package, *J. Statist. Software* 31 (2009) 1–24, <https://doi.org/10.18637/jss.v031.i07>.
- [41] L. Cohen, A. Fiore-Gartland, A.G. Randolph, A. Panoskaltis-Mortari, S.-S. Wong, J. Ralston, T. Wood, R. Seeds, Q.S. Huang, R.J. Webby, P.G. Thomas, T. Hertz, A Modular Cytokine Analysis Method Reveals Novel Associations With Clinical Phenotypes and Identifies Sets of Co-signaling Cytokines Across Influenza Natural Infection Cohorts and Healthy Controls, *Front. Immunol.* 10 (2019), <https://doi.org/10.3389/fimmu.2019.01338>.
- [42] M.D. Wilkerson, D.N. Hayes, ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking, *Bioinformatics* 26 (2010) 1572–1573, <https://doi.org/10.1093/bioinformatics/btq170>.
- [43] S.K. Kumar, B.V. Bhat, Distinct mechanisms of the newborn innate immunity, *Immunol. Lett.* 173 (2016) 42–54, <https://doi.org/10.1016/j.imlet.2016.03.009>.
- [44] R.L. Chelvarajan, S.M. Collins, I.E. Doubinskaia, S. Goes, J. Van Willigen, D. Flanagan, W.J.S. de Villiers, J.S. Bryson, S. Bondada, Defective macrophage function in neonates and its impact on unresponsiveness of neonates to polysaccharide antigens, *J. Leukoc. Biol.* 75 (6) (2004) 982–994, <https://doi.org/10.1189/jlb.0403179>.
- [45] T.R. Kollmann, B. Kampmann, S.K. Mazmanian, A. Marchant, O. Levy, Protecting the Newborn and Young Infant from Infectious Diseases: Lessons from Immune Ontogeny, *Immunity* 46 (3) (2017) 350–363, <https://doi.org/10.1016/j.immuni.2017.03.009>.
- [46] P. Tissieres, et al., Innate immune deficiency of extremely premature neonates can be reversed by interferon-gamma, *PLoS ONE* 7 (2012), e32863, <https://doi.org/10.1371/journal.pone.0032863>.
- [47] V.V. Singh, S.K. Chauhan, R. Rai, A. Kumar, S.M. Singh, G. Rai, L. Alexopoulou, Decreased pattern recognition receptor signaling, interferon-signature, and bactericidal/permeability-increasing protein gene expression in cord blood of term

- low birth weight human newborns, *PLoS ONE* 8 (4) (2013) e62845, <https://doi.org/10.1371/journal.pone.0062845>.
- [49] E. Jouanguy, F. Altare, S. Lamhamedi-Cherradi, J.L. Casanova, Infections in IFNGR-1-deficient children, *J. Interferon Cytokine Res.* 17 (1997) 583–587, <https://doi.org/10.1089/jir.1997.17.583>.
- [50] M.P. Piccinni, et al., Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones, *J. Immunol.* 155 (1995) 128–133.
- [51] M.P. Piccinni, C. Scaletti, E. Maggi, S. Romagnani, Role of hormone-controlled Th1- and Th2-type cytokines in successful pregnancy, *J. Neuroimmunol.* 109 (2000) 30–33, [https://doi.org/10.1016/s0165-5728\(00\)00299-x](https://doi.org/10.1016/s0165-5728(00)00299-x).
- [52] J.E. Mold, J.M. McCune, Immunological tolerance during fetal development: from mouse to man, *Adv. Immunol.* 115 (2012) 73–111, <https://doi.org/10.1016/B978-0-12-394299-9.00003-5>.
- [53] R. Orefice, Immunology and the immunological response to pregnancy, *Best Pract. Res. Clin. Obstet. Gynaecol.* (2020), <https://doi.org/10.1016/j.bpobgyn.2020.07.013>.
- [54] E. Rackaityte, J. Halkias, Mechanisms of Fetal T Cell Tolerance and Immune Regulation, *Front. Immunol.* 11 (2020) 588, <https://doi.org/10.3389/fimmu.2020.00588>.
- [55] N. Gomez-Lopez, D. StLouis, M.A. Lehr, E.N. Sanchez-Rodriguez, M. Arenas-Hernandez, Immune cells in term and preterm labor, *Cell. Mol. Immunol.* 11 (6) (2014) 571–581, <https://doi.org/10.1038/cmi.2014.46>.
- [56] S.A. Jones, Directing transition from innate to acquired immunity: defining a role for IL-6, *J. Immunol.* 175 (6) (2005) 3463–3468, <https://doi.org/10.4049/jimmunol.175.6.3463>.
- [57] M. Gomez de Agüero, S.C. Ganai-Vonarburg, T. Fuhrer, S. Rupp, Y. Uchimura, H. Li, A. Steinert, M. Heikenwalder, S. Hapfelmeier, U. Sauer, K.D. McCoy, A. J. Macpherson, The maternal microbiota drives early postnatal innate immune development, *Science* 351 (6279) (2016) 1296–1302, <https://doi.org/10.1126/science.aad2571>.
- [58] C.J. Stewart, et al., Temporal development of the gut microbiome in early childhood from the TEDDY study, *Nature* 562 (7728) (2018) 583–588, <https://doi.org/10.1038/s41586-018-0617-x>.
- [59] H. Rabe, A.-C. Lundell, F. Sjöberg, A. Ljung, A. Strömbeck, M. Gio-Batta, C. Maglio, I. Nordström, K. Andersson, I. Nookaew, A.E. Wold, I. Adlerberth, A. Rudin, Neonatal gut colonization by Bifidobacterium is associated with higher childhood cytokine responses, *Gut Microbes* 12 (1) (2020) 1847628, <https://doi.org/10.1080/19490976.2020.1847628>.
- [60] M. Selma-Royo, M. Calatayud Arroyo, I. García-Mantrana, A. Parra-Llorca, R. Escuriet, C. Martínez-Costa, M.C. Collado, Perinatal environment shapes microbiota colonization and infant growth: impact on host response and intestinal function, *Microbiome* 8 (1) (2020), <https://doi.org/10.1186/s40168-020-00940-8>.
- [61] N. Amenyogbe, P. Dimitriu, P. Cho, C. Ruck, E.S. Fortuno, B. Cai, A. Alimenti, H.C. F. Côté, E.J. Maan, A.L. Slogrove, M. Esser, A. Marchant, T. Goetghebuer, C. P. Shannon, S.J. Tebbutt, T.R. Kollmann, W.W. Mohn, K.K. Smolen, Innate Immune Responses and Gut Microbiomes Distinguish HIV-Exposed from HIV-Unexposed Children in a Population-Specific Manner, *J. Immunol.* 205 (10) (2020) 2618–2628, <https://doi.org/10.4049/jimmunol.2000040>.
- [62] L.S. Chollet-Hinton, A.M. Stuebe, P. Casbas-Hernandez, E. Chetwynd, M. A. Troester, Temporal trends in the inflammatory cytokine profile of human breastmilk, *Breastfeed Med.* 9 (10) (2014) 530–537, <https://doi.org/10.1089/bfm.2014.0043>.
- [63] A. Saso, O. Blyuss, D. Munblit, A. Faal, S.E. Moore, K. Le Doare, Breast Milk Cytokines and Early Growth in Gambian Infants, *Front. Pediatr.* 6 (2018), <https://doi.org/10.3389/fped.2018.00414>.
- [64] B. Dawod, J.S. Marshall, Cytokines and Soluble Receptors in Breast Milk as Enhancers of Oral Tolerance Development, *Front. Immunol.* 10 (2019) 16, <https://doi.org/10.3389/fimmu.2019.00016>.
- [65] J. Chávez-Alderete, L. Gochicoa-Rangel, R. Del-Río-Hidalgo, S. Guerrero-Zúñiga, U. Mora-Romero, R. Benítez-Pérez, L. Rodríguez-Moreno, L. Torre-Bouscoulet, M. H. Vargas, Salivary concentrations of cytokines and other analytes in healthy children, *Cytokine* 138 (2021) 155379, <https://doi.org/10.1016/j.cyto.2020.155379>.
- [66] G.Á. Martos-Moreno, V. Barrios, J. Argente, Normative data for adiponectin, resistin, interleukin 6, and leptin/receptor ratio in a healthy Spanish pediatric population: relationship with sex steroids, *Eur. J. Endocrinol.* 155 (3) (2006) 429–434, <https://doi.org/10.1530/eje.1.02227>.
- [67] N. Eshima, O. Tokumaru, S. Hara, K. Bacal, S. Korematsu, S. Karukaya, K. Uruma, N. Okabe, T. Matsuishi, L. Kazembe, Age-specific sex-related differences in infections: a statistical analysis of national surveillance data in Japan, *PLoS ONE* 7 (7) (2012) e42261, <https://doi.org/10.1371/journal.pone.0042261>.
- [68] S.L. Klein, K.L. Flanagan, Sex differences in immune responses, *Nat. Rev. Immunol.* 16 (10) (2016) 626–638, <https://doi.org/10.1038/nri.2016.90>.
- [69] V. Bhandari, Effective Biomarkers for Diagnosis of Neonatal Sepsis, *J. Pediatric Infect. Dis. Soc.* 3 (3) (2014) 234–245, <https://doi.org/10.1093/jpids/piu063>.
- [70] Q. Ye, L.-Z. Du, W.-X. Shao, S.-Q. Shang, Utility of cytokines to predict neonatal sepsis, *Pediatr. Res.* 81 (4) (2017) 616–621, <https://doi.org/10.1038/pr.2016.267>.
- [71] L.L. Raynor, J.J. Saucerman, M.O. Akinola, D.E. Lake, J.R. Moorman, K. D. Fairchild, Cytokine screening identifies NICU patients with Gram-negative bacteremia, *Pediatr. Res.* 71 (3) (2012) 261–266, <https://doi.org/10.1038/pr.2011.45>.
- [72] K.A. Simonsen, A.L. Anderson-Berry, S.F. Delair, H.D. Davies, Early-onset neonatal sepsis, *Clin. Microbiol. Rev.* 27 (1) (2014) 21–47, <https://doi.org/10.1128/CMR.00031-13>.
- [73] M.G. Netea, et al., Trained immunity: A program of innate immune memory in health and disease, *aaf1098*, *Science* 352 (2016), <https://doi.org/10.1126/science.aaf1098>.
- [74] M.G. Netea, A. Schlitzer, K. Placek, L.A.B. Joosten, J.L. Schultze, Innate and Adaptive Immune Memory: an Evolutionary Continuum in the Host's Response to Pathogens, *Cell Host Microbe* 25 (2019) 13–26, <https://doi.org/10.1016/j.chom.2018.12.006>.
- [75] M.G. Netea, J. Domínguez-Andrés, L.B. Barreiro, T. Chavakis, M. Divangahi, E. Fuchs, L.A.B. Joosten, J.W.M. van der Meer, M.M. Mhlanga, W.J.M. Mulder, N. P. Riksen, A. Schlitzer, J.L. Schultze, C. Stabell Benn, J.C. Sun, R.J. Xavier, E. Latz, Defining trained immunity and its role in health and disease, *Nat. Rev. Immunol.* 20 (6) (2020) 375–388, <https://doi.org/10.1038/s41577-020-0285-6>.